Finance
Chembio reports 19% increase in 2005 revenues
Published in AIDS Weekly, May 1st, 2006
The company's 2005 revenues were $3.94 million, a 19% increase compared to 2004 revenues of $3.31 million. For 2005, the net loss attributable to common stockholders was $6.77 million or $0.88 per share compared to a net loss attributable to common stockholders of $5.04 million or $0.85 per share for 2004. The net loss attributable to common stockholders for 2005 and 2004 includes $3.52 million and $1.94 million, respectively in non-cash dividends to preferred stockholders.
Revenues for the fourth quarter of 2005 were $1.36 million, a 17% increase...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2006-05-01)
More Articles from AIDS Weekly
- HIV/AIDS Diagnostics
Dot blot assay sensitive and specific for HIV-1 and HIV-2 antibody confirmation - HIV/AIDS Diagnostics
Rapid HIV-1/2 antibody test utilizing oral fluid samples is sensitive and specific - HIV/AIDS Immunotherapy
Antigen-loaded dendritic cells boost and broaden HIV-specific T cell response - HIV/AIDS Pathogenesis
CCR5 use by HIV-1 associated closely with gp120 V3 loop N-linked glycosylation site - HIV/AIDS-Related Wasting
Nandrolone increases fat-free mass compared with testosterone in HIV-related wasting - Adverse Drug Reaction
Adverse drug reactions to antiretroviral drugs are influenced by hepatitis virus - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
